• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西格玛-2受体/TMEM97的生物学功能及其在癌症PET成像研究中的应用

The Biological Function of Sigma-2 Receptor/TMEM97 and Its Utility in PET Imaging Studies in Cancer.

作者信息

Zeng Chenbo, Riad Aladdin, Mach Robert H

机构信息

Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

出版信息

Cancers (Basel). 2020 Jul 13;12(7):1877. doi: 10.3390/cancers12071877.

DOI:10.3390/cancers12071877
PMID:32668577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7409002/
Abstract

The sigma-2 receptor was originally defined pharmacologically and recently identified as TMEM97. TMEM97 has been validated as a biomarker of proliferative status and the radioligand of TMEM97, [F]ISO-1, has been developed and validated as a PET imaging biomarker of proliferative status of tumors and as a predictor of the cancer therapy response. [F]ISO-1 PET imaging should be useful to guide treatment for cancer patients. TMEM97 is a membrane-bound protein and localizes in multiple subcellular organelles including endoplasmic reticulum and lysosomes. TMEM97 plays distinct roles in cancer. It is reported that TMEM97 is upregulated in some tumors but downregulated in other tumors and it is required for cell proliferation in certain tumor cells. TMEM97 plays important roles in cholesterol homeostasis. TMEM97 expression is regulated by cholesterol-regulating signals such as sterol depletion and SREBP expression levels. TMEM97 regulates cholesterol trafficking processes such as low density lipoprotein (LDL) uptake by forming complexes with PGRMC1 and low density lipoprotein receptor (LDLR), as well as cholesterol transport out of lysosome by interacting with and regulating NPC1 protein. Understanding molecular functions of TMEM97 in proliferation and cholesterol metabolism will be important to develop strategies to diagnose and treat cancer and cholesterol disorders using a rich collection of TMEM97 radiotracers and ligands.

摘要

σ-2受体最初是通过药理学定义的,最近被鉴定为跨膜蛋白97(TMEM97)。TMEM97已被确认为增殖状态的生物标志物,其放射性配体[F]ISO-1已被开发并验证为肿瘤增殖状态的正电子发射断层显像(PET)成像生物标志物以及癌症治疗反应的预测指标。[F]ISO-1 PET成像应有助于指导癌症患者的治疗。TMEM97是一种膜结合蛋白,定位于包括内质网和溶酶体在内的多个亚细胞细胞器中。TMEM97在癌症中发挥着不同的作用。据报道,TMEM97在某些肿瘤中上调,但在其他肿瘤中下调,并且在某些肿瘤细胞的细胞增殖中是必需的。TMEM97在胆固醇稳态中起重要作用。TMEM97的表达受胆固醇调节信号如甾醇耗竭和固醇调节元件结合蛋白(SREBP)表达水平的调控。TMEM97通过与孕激素受体膜组分1(PGRMC1)和低密度脂蛋白受体(LDLR)形成复合物来调节胆固醇转运过程,如低密度脂蛋白(LDL)摄取,以及通过与NPC1蛋白相互作用并调节其功能来促进胆固醇从溶酶体中转运出来。了解TMEM97在增殖和胆固醇代谢中的分子功能对于利用丰富的TMEM97放射性示踪剂和配体开发诊断和治疗癌症及胆固醇紊乱的策略至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ed/7409002/1e233e806318/cancers-12-01877-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ed/7409002/11d18c9cbdb3/cancers-12-01877-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ed/7409002/028344ac4a37/cancers-12-01877-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ed/7409002/fe7f0c00f9e8/cancers-12-01877-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ed/7409002/29eec06016d8/cancers-12-01877-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ed/7409002/1e233e806318/cancers-12-01877-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ed/7409002/11d18c9cbdb3/cancers-12-01877-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ed/7409002/028344ac4a37/cancers-12-01877-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ed/7409002/fe7f0c00f9e8/cancers-12-01877-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ed/7409002/29eec06016d8/cancers-12-01877-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ed/7409002/1e233e806318/cancers-12-01877-g005.jpg

相似文献

1
The Biological Function of Sigma-2 Receptor/TMEM97 and Its Utility in PET Imaging Studies in Cancer.西格玛-2受体/TMEM97的生物学功能及其在癌症PET成像研究中的应用
Cancers (Basel). 2020 Jul 13;12(7):1877. doi: 10.3390/cancers12071877.
2
TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death.跨膜蛋白97(TMEM97)和孕酮受体膜组分1(PGRMC1)不介导σ-2配体诱导的细胞死亡。
Cell Death Discov. 2019 Jan 28;5:58. doi: 10.1038/s41420-019-0141-2. eCollection 2019.
3
Sigma-2 Receptor Ligand Binding Modulates Association between TSPO and TMEM97.Sigma-2 受体配体结合调节 TSPO 与 TMEM97 之间的关联。
Int J Mol Sci. 2023 Mar 28;24(7):6381. doi: 10.3390/ijms24076381.
4
Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex.Sigma-2 受体/TMEM97 和 PGRMC-1 通过形成三元复合物增加 LDL 受体内化 LDL 的速率。
Sci Rep. 2018 Nov 15;8(1):16845. doi: 10.1038/s41598-018-35430-3.
5
Mechanisms of Sigma-2/TMEM97 Involvement in Cholesterol Metabolism.Sigma-2/TMEM97 参与胆固醇代谢的机制。
J Cell Biochem. 2024 Oct;125(10):e30645. doi: 10.1002/jcb.30645. Epub 2024 Sep 20.
6
The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates.西格玛-2受体/TMEM97、PGRMC1和低密度脂蛋白受体复合物负责细胞对Aβ42及其蛋白质聚集体的摄取。
Mol Neurobiol. 2020 Sep;57(9):3803-3813. doi: 10.1007/s12035-020-01988-1. Epub 2020 Jun 23.
7
Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes.癌症背景下西格玛1和西格玛2/TMEM97的小分子调节剂:基础概念与新出现的主题
Front Pharmacol. 2019 Oct 21;10:1141. doi: 10.3389/fphar.2019.01141. eCollection 2019.
8
Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer.孕酮处理的正常卵巢表面上皮细胞中TMEM97与胆固醇生物合成基因的协同上调:对卵巢癌发病机制的影响
BMC Cancer. 2007 Dec 11;7:223. doi: 10.1186/1471-2407-7-223.
9
Synthesis, binding, and functional properties of tetrahydroisoquinolino-2-alkyl phenones as selective σR/TMEM97 ligands.四氢异喹啉-2-烷基苯酮作为选择性 σR/TMEM97 配体的合成、结合和功能性质。
Eur J Med Chem. 2021 Jan 1;209:112906. doi: 10.1016/j.ejmech.2020.112906. Epub 2020 Oct 7.
10
TMEM97/Sigma 2 Receptor Increases Estrogen Receptor α Activity in Promoting Breast Cancer Cell Growth.跨膜蛋白97/西格玛2受体在促进乳腺癌细胞生长过程中增强雌激素受体α活性。
Cancers (Basel). 2023 Dec 2;15(23):5691. doi: 10.3390/cancers15235691.

引用本文的文献

1
Recent Advances in the Development of Sigma Receptor (Radio)Ligands and Their Application in Tumors.σ受体(放射性)配体的开发进展及其在肿瘤中的应用
ACS Pharmacol Transl Sci. 2025 Mar 7;8(4):951-977. doi: 10.1021/acsptsci.4c00711. eCollection 2025 Apr 11.
2
Cholesterol: The driving force behind the remodeling of tumor microenvironment in colorectal cancer.胆固醇:结直肠癌肿瘤微环境重塑背后的驱动力。
Heliyon. 2024 Oct 15;10(23):e39425. doi: 10.1016/j.heliyon.2024.e39425. eCollection 2024 Dec 15.
3
Multitarget-Directed Ligands Hitting Serotonin Receptors: A Medicinal Chemistry Survey.

本文引用的文献

1
Down-regulated MAC30 expression inhibits breast cancer cell invasion and EMT by suppressing Wnt/β-catenin and PI3K/Akt signaling pathways.下调的MAC30表达通过抑制Wnt/β-连环蛋白和PI3K/Akt信号通路来抑制乳腺癌细胞的侵袭和上皮-间质转化。
Int J Clin Exp Pathol. 2019 May 1;12(5):1888-1896. eCollection 2019.
2
Breast Cancer F-ISO-1 Uptake as a Marker of Proliferation Status.乳腺癌 F-ISO-1 摄取作为增殖状态的标志物。
J Nucl Med. 2020 May;61(5):665-670. doi: 10.2967/jnumed.119.232363. Epub 2019 Dec 13.
3
Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes.
靶向血清素受体的多靶点导向配体:药物化学综述。
Pharmaceuticals (Basel). 2024 Sep 19;17(9):1238. doi: 10.3390/ph17091238.
4
Roles for PMP22 in Schwann cell cholesterol homeostasis in health and disease.PMP22 在施旺细胞胆固醇动态平衡中的作用:健康与疾病。
Biochem Soc Trans. 2024 Aug 28;52(4):1747-1756. doi: 10.1042/BST20231359.
5
Transmembrane protein TMEM97 and epigenetic reader BAHCC1 constitute an axis that supports pro-inflammatory cytokine expression.跨膜蛋白 TMEM97 和表观遗传阅读器 BAHCC1 构成了一个支持促炎细胞因子表达的轴。
Cell Signal. 2024 Apr;116:111069. doi: 10.1016/j.cellsig.2024.111069. Epub 2024 Jan 28.
6
Sigma Receptors: Novel Regulators of Iron/Heme Homeostasis and Ferroptosis.Sigma 受体:铁/血红素稳态和铁死亡的新型调节剂。
Int J Mol Sci. 2023 Sep 28;24(19):14672. doi: 10.3390/ijms241914672.
7
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.针对西格玛受体治疗神经退行性和神经发育障碍。
CNS Drugs. 2023 May;37(5):399-440. doi: 10.1007/s40263-023-01007-6. Epub 2023 May 11.
8
Sigma-2 Receptor Ligand Binding Modulates Association between TSPO and TMEM97.Sigma-2 受体配体结合调节 TSPO 与 TMEM97 之间的关联。
Int J Mol Sci. 2023 Mar 28;24(7):6381. doi: 10.3390/ijms24076381.
9
Sigma-2 Receptors-From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases.Sigma-2 受体——从基础生物学到治疗靶点:关注与年龄相关的退行性疾病。
Int J Mol Sci. 2023 Mar 26;24(7):6251. doi: 10.3390/ijms24076251.
10
The Sigma Enigma: A Narrative Review of Sigma Receptors.西格玛之谜:西格玛受体的叙述性综述
Cureus. 2023 Mar 4;15(3):e35756. doi: 10.7759/cureus.35756. eCollection 2023 Mar.
癌症背景下西格玛1和西格玛2/TMEM97的小分子调节剂:基础概念与新出现的主题
Front Pharmacol. 2019 Oct 21;10:1141. doi: 10.3389/fphar.2019.01141. eCollection 2019.
4
The Molecular Function of σ Receptors: Past, Present, and Future.σ 受体的分子功能:过去、现在和未来。
Trends Pharmacol Sci. 2019 Sep;40(9):636-654. doi: 10.1016/j.tips.2019.07.006. Epub 2019 Aug 3.
5
TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death.跨膜蛋白97(TMEM97)和孕酮受体膜组分1(PGRMC1)不介导σ-2配体诱导的细胞死亡。
Cell Death Discov. 2019 Jan 28;5:58. doi: 10.1038/s41420-019-0141-2. eCollection 2019.
6
Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [F]FLT and [F]ISO-1 PET/CT.用于监测 CDK4/6 抑制联合内分泌治疗乳腺癌反应的细胞增殖显像:[F]FLT 和 [F]ISO-1 PET/CT 的比较。
Clin Cancer Res. 2019 May 15;25(10):3063-3073. doi: 10.1158/1078-0432.CCR-18-2769. Epub 2019 Jan 28.
7
Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex.Sigma-2 受体/TMEM97 和 PGRMC-1 通过形成三元复合物增加 LDL 受体内化 LDL 的速率。
Sci Rep. 2018 Nov 15;8(1):16845. doi: 10.1038/s41598-018-35430-3.
8
Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations.Sigma-2 受体:在多种治疗开发方面的过去、现在和展望。
Future Med Chem. 2018 Aug 1;10(16):1997-2018. doi: 10.4155/fmc-2018-0072. Epub 2018 Jul 3.
9
A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting .一种多平台方法确定 miR-152-3p 作为前列腺癌中常见的受表观遗传调控的肿瘤抑制因子,针对.
Clin Epigenetics. 2018 Mar 27;10:40. doi: 10.1186/s13148-018-0475-2. eCollection 2018.
10
The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy.MAC30 在接受铂类化疗的晚期胃癌患者中的预后作用。
Future Oncol. 2017 Dec;13(29):2691-2696. doi: 10.2217/fon-2017-0426. Epub 2017 Oct 3.